ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions ...

Postmenopausal osteoporosis (PMOP) is framed as a systemic bone disease driven by estrogen withdrawal, but emerging evidence ...

Senolytic Supplements Market to Reach $350 Million by 2025, Poised for 15% CAGR Through 2032 Driven by growing focus on healthy aging and breakthroughs in cellular senescence-targeted therapies The ...